A higher risk of HF hospitalization was seen with dapagliflozin over empagliflozin, but one researcher urges caution.

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

“The most compelling evidence for the safety of SGLT2 inhibitors comes from individuals with a condition known as familial renal glucosuria, who have a defective form of SGLT2 that leads to ...

Efficacy of SGLT2 inhibitors includes reduction of HbA1c, fasting and postprandial blood glucose level and slight body weight and systolic blood pressure decrease. The most common adverse events ...

For SGLT-2 inhibitors, the most common reasons given were having an A1C ≥ 9% (42%), intolerance to the agent (19%), and financial constraints (16%). For GLP-1 agonists, the top reason given was ...

New research shows diabetes medication SGLT-2 inhibitors lower dementia risk by up to 35%, offering hope for millions ...

GLP-1RA and SGLT2 inhibitor combination therapy was associated with better cardiorenal outcomes than monotherapy among patients with type 2 diabetes. The cardiorenal benefits of sodium-glucose ...

GLP-1 receptor agonist or SGLT2 inhibitor prescribing became more common for people with type ... Not surprisingly, ...

A FAQ section has been added for common medications, addressing popular customer inquiries that provides a deeper insight into its use for SGLT2 Inhibitors: An Evolution in Diabetes Mellitus?

[24,25] Here, we hypothesized that common SGLT2 variants ... by SGLT2 inhibitors, [26] the study could provide a valuable basis for further pharmacogenetic studies. Furthermore, most of the ...